We can’t show the full text here under this license. Use the link below to read it at the source.
Glucagon-like Peptide-1 Receptor Agonists in Heart Failure: Mechanisms, Evidence and Identifying Optimal Candidates
How Glucagon-like Peptide-1 Receptor Agonists May Help Heart Failure: How They Work, Evidence, and Finding the Best Patients
AI simplified
Abstract
Glucagon-like peptide-1 receptor agonists () significantly improve symptoms and outcomes in heart failure with preserved ejection fraction () in patients with obesity and/or type 2 diabetes.
- GLP-1RAs are linked to significant weight loss and blood pressure reduction.
- Enhanced glycaemic control and anti-inflammatory effects may contribute to heart failure improvement.
- Dedicated trials confirm the efficacy of GLP-1RAs specifically in HFpEF patients with obesity and/or diabetes.
- Some trials showed GLP-1RAs significantly improved heart failure symptoms and reduced heart failure events.
- Current evidence does not support the use of GLP-1RAs for heart failure with reduced ejection fraction.
AI simplified
Key numbers
3–5 kg
Weight Loss with
Weight loss achieved with shorter-acting .
7.8 points
KCCQ-CSS Improvement
Change in KCCQ-CSS in the STEP- trial vs. placebo.
33%
Hospitalization Risk Reduction
Relative risk reduction in the SUMMIT trial.